- Chief Compliance Officer and VP of Legal Affairs, Arrow Electronics
By 
Adrianne Appel2023-03-28T18:43:00
Laboratory Corporation of America (Labcorp) agreed to pay $2.1 million to settle allegations the company overbilled the Department of Defense (DoD) for genetic tests performed by a third party.
The Department of Justice (DOJ) announced the settlement Monday for violations of the False Claims Act (FCA). The complaint against Labcorp was originally filed by a former employee, Donna Hecker-Gross, under the qui tam provisions of the FCA. Hecker-Gross will receive $357,000 from the settlement amount.
The details: Labcorp entered into a contract with the DoD in 2012 to provide testing services for U.S. military worldwide. The company then subcontracted with GeneDx to conduct specialty genetic tests. GeneDx billed LabCorp for the tests, and Labcorp would then bill the DoD.
THIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.
News and analysis for the well-informed compliance or audit exec. Select an option and click continue.
Annual Membership $499 Value offer
Full price one year membership with auto-renewal.
Membership $599
One-year only, no auto-renewal.
The former director of quality assurance at Magellan Diagnostics allegedly conspired with executives to conceal a critical flaw in lead tests they knew would result in tens of thousands of false negative tests among lead-exposed children.
Genotox Laboratories agreed to pay at least $5.9 million to settle charges it violated the False Claims Act by paying volume-based commissions to third-party marketers and submitting claims to federal healthcare programs for unnecessary drug tests.
Michigan-based Covenant Healthcare System paid $69 million to settle whistleblower allegations it engaged in illegal referral and kickback schemes.
USAA Federal Savings Bank has been hit with its third cease and desist order from the Treasury Department’s Office of the Comptroller of the Currency in the past five years for failing to correct unsafe and unsound banking practices.
Becton Dickinson medical device company will pay $175 million for “repeatedly” misleading investors about its Alaris infusion pump, a product the company knew was flawed and was sold without the required patient-safety approvals, the Securities and Exchange Commission said.
The Securities and Exchange Commission charged bankrupt fashion retailer Express with failing to disclose nearly $1 million in perks to a former chief executive, but did not levy a financial penalty thanks to its cooperation, the SEC said.
